开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Veerdonk Garbino
Urinary tract infections (UTIs) caused by Escherichia coli (E. coli) are a pervasive global health issue, presenting clinical challenges due to antibiotic resistance. This article explores clinical perspectives on E. coli UTIs and innovative treatment approaches. Traditional antibiotics, once effective, are facing increasing resistance. Innovative solutions, including fosfomycin, phage therapy, vaccines, probiotics, CRISPR-based therapies, and nanotechnology, offer potential breakthroughs. A patient-centered approach, coupled with prevention strategies, is essential in E. coli UTI management. These innovative treatments represent promising advancements in the field, highlighting the potential for more effective solutions to combat E. coli UTIs.